UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2151-9
Program Prior Authorization/Medical Necessity
Medication Yupelri® (revefenacin inhalation solution)
P&T Approval Date 9/2018, 1/2019, 7/2019, 8/2020, 11/2020, 11/2021, 11/2022, 11/2023,
11/2024
Effective Date 2/1/2025
1. Background:
Yupelri (revefenacin inhalation solution) is a nebulized long-acting antimuscarinic
(anticholinergic) agent indicated for the maintenance treatment in patients with chronic
obstructive pulmonary disease (COPD).
2. Coverage Criteriaa:
A. Initial Authorization
1. Yupelri will be approved based on all of the following criteria:
a. Diagnosis of moderate to severe chronic obstructive pulmonary disease (COPD)
- AND-
b. One of the following:
1) History of failure, contraindication or intolerance to Spiriva Handihaler or
Respimat (tiotropium)
- OR-
2) Patient is unable to use a metered-dose, dry powder or slow mist inhaler (e.g.
Spiriva Respimat) to control his/her COPD due to one of the following:
a) Cognitive or physical impairment limiting coordination of handheld devices
(e.g., cognitive decline, arthritis in the hands) (Document impairment)
b) Patient is unable to generate adequate inspiratory force (e.g., peak
inspiratory flow rate (PIFR) resistance is <60 L/min)
Authorization will be issued for 12 months
B. Reauthorization
1. Yupelri will be approved based on the following criterion:
a. Documentation of positive clinical response to therapy
© 2024 UnitedHealthcare Services Inc.
1
Authorization will be issued for 12 months
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Global strategy for the diagnosis, management and prevention of COPD. Global Initiative for
Chronic Obstructive Lung Disease (GOLD). 2024.
2. Yupelri [package insert]. Morgantown, WV: Mylan Specialty L.P.; May 2022.
3. Ferguson GT, Goodin T, Tosiello R, et al. Long-term safety of glycopyrrolate/eFlow CS in
moderate-to-very severe COPD: results from the glycopyrrolate for obstructive lung disease
via electronic nebulizer (GOLDEN) 5 randomized study. Respiratory Medicine 132;
2017:251-60.
4. Wise RA, Acevedo RA, Anzueto AR, et al. Guiding principles for the use of nebulized long-
acting beta2-agonists in patients with COPD: An expert panel consensus. Chronic Obstr
Pulm Dis 2017; 4(1): 7-20
Program Prior Authorization/Medical Necessity –Yupelri
Change Control
Date Change
9/2018 New program
1/2019 Added Yupelri to the criteria.
7/2019 Removed ipratropium as a step 1 option, added Yupelri as step 1 option
prior to Lonhala Magnair and noted that Lonhala Magnair is typically
excluded from coverage.
8/2020 Annual review. Updated references and removed step through Seebri
Neohaler due to removal from the market.
10/2020 Formatting update.
11/2021 Annual review. Updated references.
11/2022 Annual review. Removed Incruse Ellipta as a step first-line agent.
Updated references.
11/2023 Annual review. Updated references.
11/2024 Annual review. Removed Lonhala Magnair. Updated references.
© 2024 UnitedHealthcare Services Inc.
2